Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
BACKGROUND
The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF).


METHODS
Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results.


RESULTS
Ten patients were treated with CCRT using TPF regimen. The 5-year overall survival rate and disease-free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5-year overall survival rate was 56%.


CONCLUSION
The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen. © 2015 Wiley Periodicals, Inc. Head Neck 38: E949-E953, 2016.
['Shinomiya|Hirotaka|H|', 'Hasegawa|Shingo|S|', 'Yamashita|Daisuke|D|', 'Ejima|Yasuo|Y|', 'Kenji|Yoshida|Y|', 'Otsuki|Naoki|N|', 'Kiyota|Naomi|N|', 'Sakakibara|Shunsuke|S|', 'Nomura|Tadashi|T|', 'Hashikawa|Kazunobu|K|', 'Kohmura|Eiji|E|', 'Sasaki|Ryohei|R|', 'Nibu|Ken-Ichi|K|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D001859:Bone Neoplasms D002294:Carcinoma, Squamous Cell D059248:Chemoradiotherapy D002945:Cisplatin D018572:Disease-Free Survival D005260:Female D005472:Fluorouracil D006258:Head and Neck Neoplasms D006801:Humans D008297:Male D008875:Middle Aged D012189:Retrospective Studies D015996:Survival Rate D043823:Taxoids D013701:Temporal Bone
concomitant chemoradiotherapy temporal bone cisplatin docetaxel ear cancer